Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SOAR

Financiado

Systematic Triangulation of Pathobiont-Host-Interactions

Rising incidences of chronic disorders and cancer have been linked to reduced microbial diversity. Genetic risk factors are similarly involved in the development of chronic disorders and cancer. The effect of both microbial and ge... ver más

31/12/2028

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-29

ERC-2023-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

1.99M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RYC-2010-07051 Role of the intestinal microbiota in inflammatory bowel dise... Cerrado

CD-ResOMics Elucidating the cellular basis of therapeutic resistance in... 173K€ Cerrado

FLAMINCO Therapeutic discovery for Inflammatory Bowel Disease 150K€ Cerrado

AGL2008-01440 MECANISMOS DE ACCION DE BACTERIAS INTESTINALES Y PROBIOTICAS... 157K€ Cerrado

RTI2018-101586-A-I00 CONTROL PRECISO DE LA NATURALEZA DE LA AUTOFAGIA EN LA HOMEO... 157K€ Cerrado

PID2021-123918OB-I00 ESTUDIO DE LA HETEROGENIDAD EN LA ENFERMEDAD INFLAMATORIA IN... 339K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2023-09-29
Fecha Fin: 2028-12-31

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Rising incidences of chronic disorders and cancer have been linked to reduced microbial diversity. Genetic risk factors are similarly involved in the development of chronic disorders and cancer. The effect of both microbial and genetic factors is particularly evident in inflammatory bowel disease (IBD) and colorectal cancer (CRC). However, the identification of specific bacteria that trigger/drive disease or modulate therapy efficacy in IBD and CRC lacks a comprehensive approach. Even less is known about how these bacteria mechanistically induce such effects. The paucity of so far identified disease relevant bacteria and their mode of action, likely lies in the complexity of both the microbiome and the host’s genetic risk factors. We hypothesize that specific bacteria, which do not harm the host under steady state conditions, hijack host pathways in the presence of certain genetic risk factors to drive inflammation, onset and progression of IBD and CRC. We speculate that these bacteria, termed pathobionts, have so far been overlooked due to a lack of methods to triangulate these disease relevant bacteria in multi-factorial disorders like IBD and CRC. It is our objective to identify these pathobionts and match them to host genetic risk. To do so, we have developed an antibody coating based approach, to identify and culture pathobionts. Now, we want to overhaul our approach to develop a high throughput-pathobiont identification technology. Through machine learning, we then aim to find pathobiont-host genetic risk matches that drive disease and validate these matches in vivo. Lastly, we plan to demonstrate the potential of our new technology and gained knowledge. Through leveraging the gained knowledge, we aim to identify pathobiont-host risk matches in publicly available databases. This will unmask individuals at risk for the development of IBD, CRC and potentially other disorders. This may pave the way for future microbiome-based precision medicine approaches.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores